Clinical Trial

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-24; most recent amendment 2026-02-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-12
Trial Details
NCT Number NCT07204418
Lead Sponsor Karuna Therapeutics
Conditions Healthy Volunteers
Enrollment 56 participants
Start Date 2025-10-13
Primary Completion 2026-12-03 (estimated)
Study Completion 2026-12-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-19